Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled crossover trial

Post time The day before yesterday 00:39

journal：The Lancet Respiratory Medicine

Authors: Felix C Ringshausen MD, Adam J Shapiro MD, Prof Kim G Nielsen DrMedSci, Prof Henryk Mazurek MD, Massimo Pifferi Ph, Karl H Donn Ph, Menno M van der Eerden M, Prof Michael R Loebinger Ph, Prof Maimoona A Zariwala PhD, Prof Margaret W Leigh MD, Prof Michael R Knowles MD, Prof Thomas W Ferkol MD

Published date：2023-8-31

DOI：10.1016/S2213-2600(23)00226-6

PDF link：https://www.sciencedirect.com/science/article/pii/S2213260023002266/pdf

Article link：https://dx.doi.org/10.1016/S2213-2600(23)00226-6

Article Source：Elsevier。

Remark：

Post time The day before yesterday 00:39

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Elsevier] Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled crossover trial

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Elsevier] Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled crossover trial Copy

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Elsevier] Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled crossover trial